European Progress On Biosimilars Is Just The Beginning

Europe can build on the last 20 years of progress to realize even greater potential for biosimilars in the next decade – but only if a comprehensive strategy for biosimilars is put in place. That was the message delivered by industry association Medicines for Europe at its 20th annual biosimilar medicines conference in Amsterdam.

Speaking at the conference in April, Isabell Remus – chair of Medicines for Europe’s biosimilar medicines sector group and head of biopharma and specialty at Sandoz – highlighted the opportunities that were on the horizon for biosimilars in Europe, as the industry looked to